Histology
Carcinoma of Unknown Primary
CI-CAN-00002109Explore in graph →
4,156 active trials54 approved drugs532 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00002109Explore in graph →
Clinical trials
14,232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,893)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05963867 | A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer | recruiting | Phase 1 | 12 | Boehringer IngelheimINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06179069 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | recruiting | Phase 1 | 339 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 3 | Aug 21, 2026 | clinicaltrials |
| NCT06432036 |
| Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial |
| recruiting |
| Phase 1 / Phase 2 |
| 25 |
| Jonsson Comprehensive Cancer CenterOTHER |
| 1 |
| Aug 21, 2026 |
| clinicaltrials |
| NCT07531095 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)(DeLLphi-313) | recruiting | Phase 1 | 160 | AmgenINDUSTRY | 9 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06225011 | Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer | recruiting | Phase 1 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07619313 | AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer | recruiting | Phase 1 | 46 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06922539 | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer | recruiting | Phase 1 | 44 | SciTech Development, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT07214298 | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06218303 | Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ | recruiting | Phase 1 | 50 | Finn, Olivera, PhDOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06427798 | Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | recruiting | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06764316 | A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer(BANTAM-01) | recruiting | Phase 1 | 148 | BayerINDUSTRY | 9 | Aug 18, 2026 | clinicaltrials |
| NCT06966024 | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | recruiting | Phase 1 | 60 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07182149 | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | recruiting | Phase 1 | 150 | Normunity AccelCo, Inc.INDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04332588 | Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI | recruiting | Phase 1 | 25 | University of Alabama at BirminghamOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT06792552 | A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 738 | NextCure, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT07157033 | A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.(XER-001) | recruiting | Phase 1 / Phase 2 | 36 | Xerient PharmaINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07341867 | Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype | recruiting | Phase 1 | 90 | Andrew Hantel, MDOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT02830724 | Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers | recruiting | Phase 1 / Phase 2 | 124 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05985655 | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors(ELUCIDATE) | recruiting | Phase 1 / Phase 2 | 230 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 13, 2026 | clinicaltrials |
| NCT06795022 | First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours(RHEA-1) | recruiting | Phase 1 / Phase 2 | 304 | AstraZenecaINDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT04199741 | PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 | recruiting | Phase 1 / Phase 2 | 105 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05859074 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | recruiting | Phase 1 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06543576 | External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer | recruiting | Phase 1 / Phase 2 | 35 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07155200 | Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) | recruiting | Phase 1 / Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07600476 | A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors | recruiting | Phase 1 | 21 | Kupando GmbHINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT06236139 | Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 48 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT06257693 | Enzalutamide Implants (Enolen) in Patients With Prostate Cancer | recruiting | Phase 1 | 45 | Alessa Therapeutics Inc.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06807632 | A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer | recruiting | Phase 1 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07187869 | Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study | recruiting | Phase 1 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07195682 | A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | recruiting | Phase 1 | 281 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 11, 2026 | clinicaltrials |
| NCT07239596 | Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom | recruiting | Phase 1 / Phase 2 | 92 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05111561 | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer | recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06515990 | A Study of DM005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 208 | Doma Biopharmaceutical（Suzhou）Co., Ltd.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT07733674 | Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)(RMX-VH) | recruiting | Phase 1 | 20 | Radiomedix, Inc.INDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06188520 | A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors(CYCAD-1) | recruiting | Phase 1 / Phase 2 | 564 | AstraZenecaINDUSTRY | 5 | Aug 6, 2026 | clinicaltrials |
| NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | recruiting | Phase 1 | 30 | University of PennsylvaniaOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04999761 | AB122 Platform Study | recruiting | Phase 1 | 917 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT05318469 | Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 34 | Yuan YuanOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01) | recruiting | Phase 1 / Phase 2 | 884 | GenmabINDUSTRY | 3 | Aug 4, 2026 | clinicaltrials |
| NCT07545954 | DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer | recruiting | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Aug 4, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 21, 2026source: clinicaltrials